Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NMT2 | O60551 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17301565 | 0.94 | LMNA (0.57) | LMNAPKMCNR1HPGDNAMPT | |
| SCHEMBL28340107 | 0.88 | LMNA (0.58) | LMNAPKMCNR1HPGDNAMPT | |
| SCHEMBL26733411 | 0.86 | ALDH1A1 (0.52) | LMNAPKMCNR1HPGDNAMPT | |
| SCHEMBL13328249 | 0.86 | LMNA (0.60) | LMNAPKMCNR1HPGDNAMPT | |
| SCHEMBL16390142 | 0.85 | CNR1 (0.49) | LMNAPKMCNR1HPGDNAMPT | |
| SCHEMBL24383336 | 0.85 | LMNA (0.55) | LMNAPKMCNR1HPGDNAMPT | |
| SCHEMBL19935561 | 0.85 | LMNA (0.55) | LMNAPKMCNR1HPGDNAMPT | |
| SCHEMBL17125686 | 0.85 | CNR1 (0.69) | LMNAPKMCNR1HPGDNAAA | |
| SCHEMBL7257878 | 0.83 | ALDH1A1 (0.58) | LMNAPKMCNR1HPGDNAMPT | |
| SCHEMBL309291 | 0.83 | CNR1 (0.57) | LMNAPKMCNR1HPGDCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
| EP-0350163-A2 | Renin inhibitory peptides | BEECHAM GROUP PLC (GB) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | LMNA 528/4885PKM 4652/4885CNR1 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.